Arcutis Biotherapeutics (ARQT) said Monday it submitted a supplemental new drug application to the US Food and Drug Administration for Zoryve cream 0.05% for the treatment of mild to moderate atopic dermatitis in children aged 2 to 5 years.
The cream demonstrated consistent, rapid relief and good tolerability in prior trials, according to the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.